Yurpeak For Weight Loss: What it is, How it works, Uses, Benefits, Dosage, and Safety Guide

Yurpeak is a once-weekly injectable prescription medicine containing tirzepatide, a peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It is manufactured by Eli Lilly and marketed in India for the management of type 2 diabetes mellitus, with weight reduction as a consistently observed effect during treatment. Yurpeak is administered using a pre-filled KwikPen device alongside diet and exercise. The medicine is supplied across six dose strengths to permit individualised titration.

Yurpeak contains tirzepatide, the first approved member of a pharmacological class that simultaneously activates two incretin receptors, GIP and GLP-1, rather than just one. The molecule itself is a synthetic peptide engineered with a C20 fatty diacid side chain that binds reversibly to albumin in the bloodstream, extending its half-life to roughly five days and enabling once-weekly subcutaneous administration. By engaging two complementary metabolic pathways instead of one, tirzepatide produces effects on glycaemic control and body weight that exceeded single-incretin therapies in clinical trials.

Activation of the GLP-1 receptor enhances glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon release from alpha cells, slows gastric emptying, and acts in appetite-regulating regions of the brain to reduce hunger and food intake. Activation of the GIP receptor also enhances glucose-dependent insulin secretion and contributes to satiety and metabolic regulation. The combined effect produces a magnitude of glycaemic improvement and weight reduction that exceeds, on average, what is achievable through GLP-1 receptor activation alone in head-to-head clinical comparisons.

In adults with type 2 diabetes, this dual-receptor mechanism translates to lower HbA1c, lower fasting and post-meal glucose, and meaningful reductions in body weight. Yurpeak is initiated at a low dose and escalated gradually to improve gastrointestinal tolerability, with the patient self-administering the once-weekly injection.

Yurpeak has two principal uses in adults, with specific exclusions:

• Type 2 diabetes mellitus: As an adjunct to diet and exercise to improve glycaemic control in adults.
• Obesity and overweight: In the management of obesity and overweight in adults, the consistent reduction in appetite and food intake produces clinically meaningful weight loss alongside diet and physical activity.
• Not appropriate for: Type 1 diabetes or diabetic ketoacidosis.
• Not established in: People under 18 years of age.
• Do not combine with: Another GLP-1 receptor agonist or any other tirzepatide-containing product.

Yurpeak offers the following benefits:

• Substantial glycaemic control: In adults with type 2 diabetes, Yurpeak causes meaningful HbA1c reductions, with greater average improvement than single-incretin therapies.
• Sustained weight reduction: For adults with obesity, Yurpeak supports consistent weight loss when combined with a low-calorie diet and regular physical activity.
• Cardiometabolic improvement: Reductions in body weight, blood pressure, and waist circumference, along with improvement in glycaemic index.
• Dual incretin mechanism: Simultaneous activation of GIP and GLP-1 receptors produces greater glycaemic and weight-related effects than GLP-1-only therapies.
• Convenient dosing: Used once a week with the KwikPen design to support self-administration.
• Flexible titration: Six dose strengths allow individualised escalation that balances efficacy against gastrointestinal tolerability.

Yurpeak is injected subcutaneously once weekly, on the same day each week, at any time of day, with or without food. The injection is administered into the abdomen, thigh, or upper arm, with rotation of injection sites at each dose. The recommended starting dose is 2.5 mg once weekly for four weeks; this initiation dose is intended to improve gastrointestinal tolerability and is not used as a maintenance dose. After four weeks, the dose is increased to 5 mg once weekly. If additional clinical effect is required after a further four weeks, the dose may be escalated in 2.5 mg increments at intervals of at least four weeks, with available strengths. The maximum dose is 15 mg once weekly. The KwikPen should be stored in a refrigerator at 2°C to 8°C and protected from light; once in use, it can be kept at room temperature below 30°C for a limited period as specified in the patient information leaflet.

NOTE: "The dosage for each person varies based on their weight, desired outcome, and current health status. One must never self-administer this medication unless recommended by one's doctor."

The most frequent side effects are gastrointestinal and tend to be most prominent while increasing the dosage. However, they usually improve with continued use. These include:

• Gastrointestinal: Nausea, diarrhoea, decreased appetite, vomiting, constipation, abdominal pain, and dyspepsia (indigestion)
• Injection-site reactions: Redness, itching, or discomfort at the injection site
• General: Fatigue, dizziness, belching, and hair loss during substantial weight reduction

Serious reactions that require prompt medical attention:

• Acute pancreatitis: Presents as severe, persistent abdominal pain that may radiate to the back, with or without vomiting.
• Acute gallbladder disease: Including cholelithiasis (gallbladder stone) and cholecystitis (gallbladder inflammation), particularly with rapid or substantial weight loss.
• Acute kidney injury: Generally arises from dehydration secondary to gastrointestinal effects.
• Hypoglycaemia: Uncommon with Yurpeak alone, but more likely when combined with insulin or sulfonylureas.
• Hypersensitivity reactions: Anaphylaxis and angioedema are rare but possible.
• Worsening of diabetic retinopathy: Observed during rapid improvement in glycaemic control.
• Pulmonary aspiration: Reported in patients undergoing procedures with sedation or general anaesthesia.

Yurpeak carries a boxed warning regarding the risk of thyroid C-cell tumours observed in rat studies; the human relevance has not been established.

Contraindications

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2
• Prior serious hypersensitivity reaction to tirzepatide
• Consult your doctor before taking it during pregnancy

Use with caution in

• History of pancreatitis (discontinue if pancreatitis is suspected)
• Severe gastrointestinal disease or gastroparesis
• Diabetic retinopathy
• Renal impairment
• Planning on undergoing elective procedures with sedation or general anaesthesia (Mounjaro can delay gastric emptying, increasing the risk of pulmonary aspiration)

Drug interactions

• Insulin (SEVERE): Risk of hypoglycaemia (low blood sugar levels). Insulin dose reductions may be required when the treatment is started.
• Sulfonylureas (SEVERE): Increased hypoglycaemia risk; dose reduction often necessary.
• Oral hormonal contraceptives (CAUTION): Effectiveness may be reduced by delayed gastric emptying. Women can switch to a non-oral method or add a barrier method for four weeks after initiation and for four weeks after each dose escalation.
• Other semaglutide-containing products or GLP-1 receptor agonists (SEVERE): No added efficacy and raised adverse-effect risk; must not be combined.
• Warfarin, levothyroxine, and other narrow-therapeutic-index oral medications (CAUTION): Absorption may be altered by delayed gastric emptying; monitor clinical effect or relevant laboratory values.

Food, alcohol, and missed doses

• Adequate hydration is important to reduce the risk of dehydration-related complications from gastrointestinal effects.
• While there is no specific food restriction, large or high-fat meals can worsen nausea when the dose is being increased. Eat smaller portions slowly to avoid it.
• Alcohol may increase the risk of pancreatitis and worsen gastrointestinal effects.
• If a dose is missed and the next scheduled dose is more than two days away, take the missed dose as soon as possible.
• If less than two days remain, skip the missed dose and take the next one on the regular day.
• Two doses should never be taken on the same day.

Overdose

Overdose may result in prolonged severe gastrointestinal symptoms. The treatment may include supportive care with attention to hydration. However, symptoms may persist for several days, given the long half-life of tirzepatide. In such cases, patients should seek emergency care.

1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215866s039lbl.pdf
2. https://www.ncbi.nlm.nih.gov/books/NBK585056/
3. https://medlineplus.gov/druginfo/meds/a622044.html
4. https://www.ncbi.nlm.nih.gov/books/NBK595028/
5. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
6. https://www.nejm.org/doi/full/10.1056/NEJMoa2416394